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Abstract
Background
The spread of multi-resistant infections represents a continuously growing problem in cir-
rhosis, particularly in patients in contact with the healthcare environment.
Aim
Our prospective study aimed to analyze epidemiology, prevalence and risk factors of multi-
resistant infections, as well as the rate of failure of empirical antibiotic therapy in cirrhotic
patients.
Methods
All consecutive cirrhotic patients hospitalized between 2008 and 2013 with a microbiologi-
cally-documented infection (MDI) were enrolled. Infections were classified as Community-
Acquired (CA), Hospital-Acquired (HA) and Healthcare-Associated (HCA). Bacteria were
classified as Multidrug-Resistant (MDR) if resistant to at least three antimicrobial classes,
Extensively-Drug-Resistant (XDR) if only sensitive to one/two classes and Pandrug-Resis-
tant (PDR) if resistant to all classes.
Results
One-hundred-twenty-four infections (15% CA, 52% HA, 33% HCA) were observed in 111
patients. Urinary tract infections, pneumonia and spontaneous bacterial peritonitis were the
more frequent. Forty-seven percent of infections were caused by Gram-negative bacteria.
Fifty-one percent of the isolates were multi-resistant to antibiotic therapy (76%MDR, 21%
XDR, 3% PDR): the use of antibiotic prophylaxis (OR = 8.4; 95%CI = 1.03-76; P = 0,05) and
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current/recent contact with the healthcare-system (OR = 3.7; 95%CI = 1.05-13; P = 0.04)
were selected as independent predictors. The failure of the empirical antibiotic therapy was
progressively more frequent according to the degree of resistance. The therapy was inap-
propriate in the majority of HA and HCA infections.
Conclusions
Multi-resistant infections are increasing in hospitalized cirrhotic patients. A better knowl-
edge of the epidemiological characteristics is important to improve the efficacy of empirical
antibiotic therapy. The use of preventive measures aimed at reducing the spread of multi-re-
sistant bacteria is also essential.
Introduction
Antimicrobial resistance represents a general public health concern, although the size and the
characteristics of the problem may vary geographically, temporally and according to the
healthcare setting [1, 2]. Infections caused by resistant pathogens are usually encountered in
the hospital setting, besides, the diffusion of health-care assistance beyond the hospital is cur-
rently leading to a spread of antibiotic resistant pathogens in the general healthcare system.
This problem is associated with worse patients’ clinical outcomes during infections.
Cirrhotic patients, in their advanced stage, are highly susceptible to infections, are frequent-
ly in need of assistance from the health-care system and of antibiotic therapies (either for treat-
ment or for prophylaxis) and are subject to recurrent hospitalizations for complications of the
disease.
Several authors have recently warned for an increasing incidence of infections caused by
multi-resistant bacteria in cirrhosis [3–5].
A well-accepted definition of multi- resistant organisms is based on the resistance in vitro to
at least one agent in three or more antimicrobial categories [6, 7]. Although the names of cer-
tain multi-resistant organism describe resistance to only one agent (e.g., methicillin-resistant
Staphylococcus aureus and vancomycin-resistant enterococci), these pathogens are frequently
resistant to most available antimicrobial agents. For epidemiological purposes, due to the large
variety of the pathogens included in this group, a further sub-classification has been proposed
in recent years: pathogens non-susceptible to at least one agent in all but two or fewer antimi-
crobial categories (i.e. bacterial isolates remain susceptible to only one or two categories) are
classifiable as Extensively-drug Resistant (XDR) and those nonsusceptible to all agents in all
antimicrobial categories as Pan-drug Resistant (PDR) [8].
In the last years, epidemiology, risk factors and clinical outcomes of multi-resistant infec-
tions, particularly according to their epidemiological origin, have raised special attention in cir-
rhosis. The above proposed classification could be highly relevant for epidemiological purposes
as it introduces a harmonized terminology, takes into consideration the severity of bacterial re-
sistance and therapeutic consequences.
To the best of our knowledge, we applied the classification in MDR, XDR and PDR in cir-
rhotic patients for the first time, describing a high rate of MDR and XDR infections [9]. A re-
cent retrospective study limited to bloodstream infections, also reported a high rate of Gram
negative MDR and XDR pathogens among cirrhotic patients [10].
Our study was carried out prospectively in order to assess characteristics, risk factors and
outcome of multi- resistant infections in a large series of hospitalized cirrhotic patients. For
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this aim we considered only patients with microbiologically documented infections (MDI). Ep-
isodes of infection were classified according to the different degree of multi-resistance (MDR,
XDR, PDR). The efficacy of currently recommended empirical antibiotic therapy was also
evaluated.
Patients and Methods
Patients
All cirrhotic patients consecutively admitted to our Department University hospital from Oc-
tober 2008 to June 2013, were considered for enrollment. Only patients admitted with MDI or
developing it during hospitalization were included in the study.
Concomitant immunosuppressant conditions (HIV infection, high dose corticosteroid
treatment and other immunosuppressive therapies) and hepatocellular carcinoma out of the
Milan criteria were considered as exclusion criteria.
At admission, relevant baseline demographic, clinical and biochemical data were recorded.
The data collection was performed taking carefully into account the possible risk factors for in-
fections caused by multi-resistant bacteria (site of acquisition of the infection, recent use of an-
tibiotics, previous hospitalization, previous infections, invasive procedures, long-term
quinolone-prophylaxis). The severity of liver disease was assessed using the Child–Pugh and
the model of end-stage liver disease (MELD) scores.
The study was approved by the local Ethical Committee Review Board (Policlinico Umberto
I) and a written informed consent was obtained by all the participants to allow the collection of
their individual data pertaining their previous history and hospitalization.
Assessment of infections and antibiotic treatments
Episodes of infections were always actively sought out either at admission or during the
hospital stay.
A detailed form concerning the infectious episodes, was compiled including the epidemio-
logical characteristics, the site of infection, the result of positive microbiology cultures, the re-
sults of white blood cells count and inflammatory indices, the antibiotic therapy. Information
regarding the clinical events during hospitalization were also collected (i.e., efficacy of the ini-
tial empirical antibiotic therapy, complications related to infection, resolution, and hospital
mortality).
The diagnosis of bacterial infection was based on previously reported standard criteria [3].
According to their epidemiological characteristics, infections were classified as follows: (1)
Hospital acquired (HA) in case of infection onset at least 48 hours after the admission, or within
10 days of leaving the hospital, or if the patient was coming from another department. (2)
Health-care associated (HCA) if the diagnosis was made at hospital admission or within 48
hours of hospitalization in patients with any of the following criteria: a) had attended a hospital
or a hemodialysis clinic or received intravenous chemotherapy in the last 30 days, b) was hospi-
talized for at least two days or had undergone surgery during the 90 days before infection or c)
had resided in a nursing home or a long-term care facility. (3) Community acquired (CA) if the
diagnosis of infection was made within 48 hours of hospitalization and the patient did not fulfil
the criteria for HCA infection (had no recent contact with the health-care system) [11, 12].
Prophylaxis and treatment of infections
Patients with a history of gastrointestinal bleeding or previous spontaneous bacterial peritonitis
(SBP) or subjected to invasive procedures for which prophylaxis was indicated, were treated
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with antibiotic therapy according to the general guidelines or our hospital protocol for invasive
procedures.
When an infection was suspected, after a prompt collection of the culture specimens, pa-
tients were immediately treated with broad-spectrum antibiotics according to the likely site of
infection, in accordance with current guidelines [13] and considering the local epidemiology.
Antimicrobial treatment before the result of cultures and the tests of the in vitro susceptibility
was considered empirical, and became definite only when this information was available. Em-
pirical antibiotic treatment was considered appropriate only when the isolated bacteria was
found to have in vitro susceptibility to that antibiotic. If not the antibiotic therapy was accord-
ingly changed.
Classification of multi-resistance
We considered “multi-resistant” all pathogens resistant to three or more antimicrobial classes.
Among them, according to the international classification of the different degrees of multi-
resistance, infections were divided as follows [8]: (a) "Multidrug-resistant" (expressed as MDR)
if the pathogen was resistant to three or more antimicrobial classes, but susceptible to at least
three classes. (b) "Extensively Drug-Resistant" (XDR) when the pathogen was sensitive only to
one or two classes. (c) "Pandrug-Resistant" (PDR) when the pathogen was resistant to all
antimicrobial classes.
For these definitions, bacterial isolates were considered resistant to an antimicrobial class
when they were not susceptible to at least one member of the class.
Statistical analysis
All the values are reported as means ± SD and p values<0,05 were considered
statistically significant.
Differences among CA/HA/HCA groups were compared using the chi-squared test or
ANOVA. Rejection of the null hypothesis implies that at least one of the three groups was dif-
ferent from the other two. When the hypothesis was significant, we performed post-hoc multi-
plicity adjusted multiple comparison.
Differences between MDR and XDR groups were evaluated by means of the Student’s test
for unpaired data or the chi-squared test, as appropriate. The paired sample t-test was used to
longitudinally compare psychometric performances. The correlation between psychometric
tests and inflammatory indices was analyzed by Pearson’s correlation Logistic regression analy-
sis was employed to identify possible predictors of the cognitive impairment. We do not further
adjust for multiple comparison with respect to the outcomes considered and report raw p-val-
ues, as any adjustment would lead to the same conclusions regarding statistical significance.
The software used for the analysis was NCSS (Number Cruncher Statystical System) 2007.
Results
Patients
During the enrollment period, 424 cirrhotic patients, were hospitalized in our ward. Twenty-
five patients were excluded: 5 because of the concomitant use of immunosuppressive medica-
tions and 20 because of a diagnosis of hepatocellular carcinoma out of the Milan criteria. A
bacterial infection was documented at admission or during hospitalization in 173 (39%) pa-
tients. Sixty-two patients had a culture-negative infection, 111 had a diagnosis of MDI.
Demographic characteristics and severity of liver disease were similar in patients with MDI
and in those with culture negative infections (data not shown).
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The median age of the 111 patients was 60 ± 13 years, 64% were males. Origin of liver dis-
ease was hepatitis C in 42%, hepatitis B in 10%, alcohol abuse in 23% (12% of the patients were
active alcohol abusers at the time of admission). The majority of patients had a decompensated
liver disease (53% Child-Pugh B, 36% Child-Pugh C) and the mean MELD score was 16.5 ± 7.
The main reasons for admission were the onset of portal-hypertension related complica-
tions (ascites 23.6%, hepatic encephalopathy 26.4%, acute gastrointestinal bleeding 4.5%), elec-
tive invasive procedures (10.9%), fever (7.3%) or indirect signs of infection (6.4%). At
admission, 68 patients had evidence of ascites, 73 patients had esophageal varices (in 29% large
varices at risk of bleeding). Fifty-nine patients had hepatic encephalopathy either at admission
or during hospitalization. Twenty-one patients had a diagnosis of hepatocellular carcinoma
within the Milan criteria. Forty-one patients (37%) had a diagnosis of diabetes.
Patients characteristic according to the epidemiology of the infections. The demo-
graphic, clinical and biochemical data of the patients enrolled in the study according to epide-
miological classifications of the infections are summarized in Table 1.
The patients in the three groups did not differ for age, sex, etiology of cirrhosis, reasons for
hospitalization, diagnosis of hepatocellular carcinoma and active alcohol abuse. Severity of
liver disease, as evidenced by the MELD and Child-Pugh score were also similar. HA infections
were more frequently associated with sepsis. In-hospital mortality, although higher in patients
with HA and HCA infections, was not significantly different from CA.
Microbiologically documented infections in the different epidemiological
classes
Apart from the 111 diagnosis of MDI during admission, among the enrolled populations, 13
patients experienced a second MDI during the same hospitalization. Therefore, we considered
124 episodes of infection in 111 patients.
Characteristics of the 124 MDI according to the epidemiological classes are reported in
Table 2.
Urinary tract infections (UTIs), followed by pneumonia and SBP, were the most frequent
infections in all the epidemiological classes.
Gram negative bacteria tended to be more frequent in CA and HCA infections while Gram-
positive ones in HA. In the latter group, the isolation of Gram-positive bacteria was associated
with a higher number of invasive procedures during hospitalization (2.6 ± 1.7 vs 1.9 ± 1.9,
p = 0.05).
Enterobacteriaceae (44.3%) (particularly Escherichia coli, Klebsiella pneumoniae and Proteus
mirabilis), Enterococcae (Enterococcus faecium and Enterococcus faecalis) (19.7%), Staphilococ-
cus aureus (12.3%) and coagulase-negative Staphylococci (5.7%) were the pathogens most fre-
quently responsible for infection.
Multi-resistant infections. Multi-resistant bacteria were identified in half of healthcare-
related infections (HCA and HA; Table 2).
Spontaneous bacteremia, SBP and pneumonia were the infections with the higher probabili-
ty of multiresistant bacteria (87%, 60% and 57%, respectively). At variance, UTIs were more
frequently caused by organisms sensitive to multiple antibiotic classes (57%).
Concerning the susceptibility of the isolated pathogens, Klebsiella pneumoniae and Proteus
mirabilis were multi-resistant in almost all the cases (82% and 100%, respectively), Enterococcae
and Staphylococcus aureus in about half of the cases (59% and 53%, respectively). Escherichia
coli and coagulase-negative Staphylococci were multi-resistant in 38% and 29%, respectively.
As shown in Table 3, the current or previous contact with the healthcare environment (HA
or HCA infections) (p = 0.02), the use of antibiotics in the last month (p = 0.04) and the
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chronic antibiotic prophylaxis (p = 0.01) were factors associated with multi-resistant infections
at univariate analysis.
Healthcare associated origin of the infection (HA and HCA) (OR 3.7; 95% CI 1.05–13;
P = 0.04) and the use of antibiotic prophylaxis (OR 8.4; 95% CI 1.03–76; P = 0.05) were selected
as independent predictors for the development of bacterial multi-resistant infections at multi-
variate analysis.
Epidemiology of various degrees of multi resistance. Applying the classification of
multi-degree of resistance, we observed 47 MDR, 15 XDR and 2 PDR.
Table 1. Demographic, clinical and biochemical characteristics of the 111 patients enrolled in the study according to the epidemiological class of
the first infection: Community Acquired (CA), Hospital Acquired (HA) and Healthcare Associated (HCA).
CAI (18) HAI (51) HCAI(42) P (*)
Males, n (%) 11 (61) 35 (69) 24 (58) n.s.
Age (years) 60.7 ± 19 58.4 ± 14 62.2 ±10 n.s.
Main etiology of the liver disease, n (%) n.s.
HBV 2 (11) 5 (10) 2 (5)
HCV 7 (39) 19 (37) 18 (44)
HBV and HCV 1 (5.5) 2 (4) 1 (2.5)
Alcohol 4 (22) 10 (20) 11 (27)
Others 4 (22) 15 (29) 9 (21.5)
Main cause of admission, n (%) n.s.
Ascites 5 (28) 12 (23.5) 9 (22)
Hepatic encephalopathy 6 (33) 8 (16) 15 (37)
Variceal bleeding 0 (0) 5 (10) 0 (0)
Suspected infections 2 (11) 6 (12) 7 (17)
Elective procedures 1 (6) 7 (14) 4 (10)
Other 4 (22) 13 (25.5) 6 (15)
Child-Pugh class C, n (%) 2 (11) 21 (41) 17 (41) n.s.
MELD score 14.8 ± 8.5 17.5 ± 8.1 15.7 ± 4.5 n.s.
Serum bilirubin (mg/dL) 5.7 ± 12.5 10 ± 17.4 4.8 ± 4.6 n.s.
Serum albumin (mg/dL) 3.1 ± 0.6 3.1 ± 0.8 3.5 ± 4.1 n.s.
International Normalized Ratio 1.5 ± 0.4 1.6 ± 0.5 2 ± 2.1 n.s.
Platelets (num/mm3) 128330 ± 86500 118090 ± 128490 141330 ± 130530 n.s.
Serum creatinine(mg/dl) 1.3 ± 1.2 1.2 ± 1 1.2 ± 1.2 n.s.
Blood Urea Nitrogen (mg/dL) 35 ± 29 44 ± 36 39.5 ± 25 n.s.
Serum sodium (mmol/L) 135.7 ± 4.9 134.7 ± 5.7 130 ± 21 n.s.
Hepatocellular carcinoma, n (%) 3 (17) 12 (23.5) 6 (14.5) n.s.
Ascites, n (%) 12 (67) 33 (65) 22 (53.5) n.s.
Hepatic encephalopathy, n (%) 8 (44.5) 25 (49) 26 (63.5) n.s.
Sepsis, n (%) 5 (28) 29 (57) 11 (27) 0.01
Temperature >37,5°C, n (%) 5 (28) 13 (25.5) 10 (24.5) n.s.
Heart Rate (beats/min) 82.5 ± 11 74 ± 12 78 ± 13 0.04
Respiratory rate (breath/min) 17.8 ± 4.6 16.7 ± 2 15.9 ± 2 0.04
White Blood Cells (cell/mm3) 6105 ± 3250 5820 ± 3643 7660 ± 4350 0.08
Sedimentation rate (mm/h) 38 ± 24 26.5 ± 23 35 ± 29 n.s.
C- reactive protein 3 ± 3.7 5.5 ± 10.3 2.7 ± 2.5 n.s.
(*) p-values for testing at least one significant difference among the three groups.
doi:10.1371/journal.pone.0127448.t001
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By a time-dependent analysis, we observed, over time, a trend toward an increase in the iso-
lation of XDR/PDR pathogens. In particular, the number of XDR/PDR isolated bacteria were
almost doubled in the last two years (16% in 2008–2009 and 20% in 2010–2011 and 36% in
2012–2013).
Among the episodes due to multi-resistant pathogens, 57% of spontaneous bacteremia, 27%
of SBP, 25% of pneumonia and 15% of UTIs were re-classified as XDR.
Concerning the susceptibility of the main specific isolated pathogens, among the multi-re-
sistant ones, Staphylococcus aureus, Enterobacteriaceae, Enterococcae were re-classified as XDR
respectively in 37.5%, 27% and 11%.
Table 2. Characteristics of the 124 episodes of infections according to the epidemiological class (community-acquired (CA), hospital acquired
(HA), healthcare associated (HCA) infections).
CA (18) HA (64) HCA (42) P (*)
Urinary tract infections, n (%) 12 (67) 33 (51) 31 (75.5) 0.03
Pneumonia, n (%) 1 (5.5) 10 (16) 4 (7) n.s.
Spontaneous bacterial peritonitis, n (%) 3 (17) 4 (6.5) 3 (7) n.s.
Spontaneous bacteraemia, n (%) 1 (5.5) 7 (11) 0 (0) n.s.
Biliary tract infections, n (%) 0 (0) 2 (3) 0 (0) n.s.
Other infections, (Skin, gastrointestinal, lymphagitis, bursitis), n (%) 1 (5.5) 8 (13) 4 (10) n.s.
Gram positive/ negative// Mixed, n (%) 5 (28)/ 13 (72)/ 0 (0) 38 (59)/ 22 (35)/ 4 (6) 15 (37)/ 23 (54)/4 (10) n.s.
Enterobacteriaceae 13 (72) 20 (32) 22 (51) 0.005
E. coli 12 (67) 14 (22) 16 (37) 0.001
K. pneumoniae 1 (6) 5 (8) 3 (7) n.s.
P. mirabilis 0 (0) 1 (2) 3 (7) n.s.
Enterococcus 2 (11) 14 (21) 9 (22) n.s.
Enterococcus +Enterobacteriaceae 0 (0) 4 (6.5) 3 (7) n.s.
S. aureus 2 (11) 12 (19) 1 (2.5) 0.04
Coagulase neg staphylococcus 1 (5.5) 3 (5) 3 (7) n.s.
Other 0 (0) 11 (17.5) 4 (10) n.s.
Multi-resistant infections, n (%) 4 (22) 34 (53) 26 (62) 0.008
(*) p-values for testing at least one significant difference among the three groups.
doi:10.1371/journal.pone.0127448.t002
Table 3. Possible risk factors and outcomes of multi-resistant and nonmulti-resistant infections.
Multi-resistant infections (64) Non Multi-resistant infections (60) P
CAI/ HAI/ HCAI 4 (6.5)/ 34 (53)/ 26 (40) 14 (23)/ 30 (50)/ 16 (27) 0.02
Use of antibiotics in the last 30 days, n (%) 24 (39) 13 (22) 0.04
Antibiotic prophylaxis, n (%) 9 (14.5) 1 (2) 0.01
Hospitalizations in the last 6 months, n (%) 40 (64.5) 38 (63) n.s.
Infections i the last 12 months, n (%) 25 (40) 25 (42) n.s.
Failure of empirical antibiotic therapy, n (%) 37 (58) 22 (37) 0.004
Deterioration of Child-Pugh score, n (%) 34 (55) 18 (35) 0.005
Deterioration of MELD score, n (%) 34 (55) 21 (35) 0.01
Deterioration in renal function, n (%) 11 (17) 8 (13) n.s.
In-hospital mortality, n (%) 19 (30) 11 (18) n.s
Hospital stay (from the diagnosis of infection) (days) 20.2 ± 21.6 17.8 ± 13 n.s.
doi:10.1371/journal.pone.0127448.t003
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No specific risk factors for the severity of the degree of multi-resistance could be found in
our cohort (Table 4).
Empirical antibiotic failure and outcomes in multi-resistant infections. As expected, a
higher rate of failure of empirical antibiotic therapy was observed in patients with MDR (60%)
and in XDR infections (90%) compared to patients with an infection due to a non multi-resis-
tant pathogen (37%) (Tables 3 and 4).
A deterioration of liver function was documented in patients with multi-resistant infections.
There was a trend to a higher occurrence of deterioration of renal function, to a longer hospital
stay (time between diagnosis of infection and discharge) and to a higher mortality rate, al-
though without reaching statistical significance, during hospitalization in the multi-resistant
group compared to non multi-resistant and in XDR group vs MDR (Tables 3 and 4).
Specifically, we observed a significantly higher rate of deterioration of renal function (23%
vs 7%; p = 0.02), a longer hospital stay (20.6 ± 14 vs 13.6 ± 11; p = 0.003) and a higher in-hospi-
tal mortality (35% vs 10%, p = 0.001) in case of failure of the empirical antibiotic treatment.
Discussion
While a significant improvement in the clinical management of cirrhotic patients has been
seen in recent years, bacterial infections are still very frequent and cause severe complication in
this group of patients [3].
In cirrhotic patients, the infections caused by multi-resistant pathogens represent a growing
problem, even more than in the general population. In the last decade, several studies have ad-
dressed the epidemiological characteristics of infections and the prevalence of antibiotic resis-
tances in patients with cirrhosis [3–5, 10, 14]. However, the microbiological characteristics
may largely vary according to time and place, so the best way to drive the empirical antibiotic
therapy is to known the actual local epidemiology.
Our single centre prospective study, was aimed to assess epidemiological characteristics,
risk factors and outcomes of multi-resistant infections in hospitalized cirrhotic patients.
For these aims, we considered all infectious sites and not only bloodstream infections or
SBP, as in previous studies [4, 10]: UTIs and pneumonia were the prevalent infections in our
cohort. UTIs are the most frequent type of infection in the majority of the clinical records, rep-
resenting one of the main reason for administering empirical antibiotic therapy. Therefore, we
think that the inclusion of this kind of infection enhances the clinical strength of our study.
Table 4. Possible risk factors and outcomes of Multi-Drug Resistant (MDR) and Extensively- Drug Resistant (XDR) infections (Pan-drug Resistant
infections were not considered due to the small sample size).
MDR (47) XDR (15) P
CAI/ HAI/ HCAI, n (%) 2 (4)/ 26 (55)/ 19 (40.5) 2 (13)/ 7 (47)/ 6 (40) n.s.
Antibiotic prophylaxis, n (%) 9 (19) 0 (0) n.s.
Additional bed, n (%) 20 (42.5) 10 (67) n.s.
Use of antibiotics in the last 30 days, n (%) 18 (38) 6 (40) n.s.
Hospitalizations in the last 6 months, n (%) 33 (70) 7 (47) n.s.
Infections in the last 12 months, n (%) 19 (40,5) 6 (40) n.s.
Failure of empirical antibiotic therapy, n (%) 28 (60) 14 (93) 0.01
Deterioration in renal function, n (%) 8 (17) 3 (20) n.s.
In-hospital mortality, n (%) 12 (25) 6 (40) n.s.
Hospital stay (from the diagnosis of infection) (days) 17.8 ± 12.7 28 ± 37.8 n.s.
doi:10.1371/journal.pone.0127448.t004
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Concerning the microbiological characteristics of our cohort, Enterobacteriaceae, followed
by Enterococcae, were the pathogens most often responsible for infections. At the same time, as
previously described, a growing prevalence of non-enterococcal Gram-positive bacteria (Staph-
ylococcus aureus and coagulase-negative Staphylococci) was observed, particularly in the set-
ting of HA infections and especially in patients undergone to multiple invasive procedures [5,
15]. A multi-resistant pathogen was isolated in about half of patients. This percentage is much
higher than that reported by the majority of studies conducted in other countries [4, 5, 15, 16],
due to the higher prevalence of multi-drug resistance in our hospital and to the epidemiological
characteristics of the enrolled patients (high rate of HCA and HA infections). As we previously
reported, the majority of multi-resistant infections occurred, in fact, in patients hospitalized or
with a recent contact with the hospital environment (53% in HA, 62% in HCA vs 22% in CA).
A current or previous contact with the healthcare environment and the use of an antibiotic
prophylaxis were both selected among the independent risk factors for multi-resistant bacterial
infections suggesting a relevant role for the antibiotic pressure present in both this conditions.
Applying the international classification proposed in general population [8] to further strat-
ify the multiresistant infections, we documented that a relevant amount of multi-resistant in-
fections were XDR (when the pathogen was sensitive only to one or two classes) and that this
percentage was doubling in the last years as shown by a time-dependent analysis. No specific
risk factors for the severity of the degree of multi-resistance could be found in our cohort, prob-
ably due to the small size of this group.
As shown in our study, the increase in the prevalence of MDR and XDR infections among
cirrhotic patients is associated to a more frequent failure of empirical antibiotic therapy. A de-
terioration of liver function was documented in patients with multi-resistant infections. A
higher morbidity and mortality was observed progressively in patients with MDR and XDR,
particularly in case of failure of the empirical antibiotic treatment.
In summary, although the results of the current study, deriving from a single centre experi-
ence with a specific microbiological pattern, cannot be generalized, our study may provide sev-
eral practical messages.
First, the high incidence of infections related to the healthcare system (HA and HCA) and
their close relationship with multi-resistance underline the need to improve preventive mea-
sures against bacterial infections in hospital setting. A relocation of care from hospital to the
home assistance and a better use of isolation precautions during hospitalization may be essen-
tial to limit the spread of multi-resistant organisms. Hygienic measures, the use of catheters
(both urinary and vascular) only when strictly necessary and the removal of these devices as
soon as possible, may be the first steps. Furthermore, the indications for antibiotic prophylaxis
should be carefully evaluated accordingly to the actual context. Second, the knowledge of the
own epidemiology is extremely important considering the high clinical relevance of a correct
empirical antibiotic therapy. In this scenario, a better stratification of the multi resistances may
allow to better characterized this growing problem. Moreover, the high rate of first line antibi-
otic treatment failure in HCA, would imply the need for second-line therapies as well as in HA,
although randomized trial are needed.
Third, as emphasized in the general population [17], the risk of a rapid increase in patho-
gens potentially resistant to every drug on the market is increasing due to a “delay” in the de-
velopment of new antimicrobial classes. Anyway, in our study, although the number of XDR
pathogens was relevant, the rate of PDR was still low leaving a little space to apply preventive
measures.
An additional factor of improvement, finally, can be derived from the acquisition of the
technology (now already available in several centers) needed to speed up bacterial isolation to
quickly use of targeted antibiotic therapy.
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